Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18827057 | 0.81 | ALOX15 (0.36) | ALOX15ALDH1A1LMNATHRBMAPK1 | |
| SCHEMBL17340687 | 0.78 | ALOX15 (0.31) | ALOX15 | |
| SCHEMBL17340719 | 0.78 | ALOX15 (0.51) | ALOX15ALDH1A1LMNATHRBMAPK1 | |
| SCHEMBL10086308 | 0.75 | ALOX15 (0.35) | ALOX15ALDH1A1LMNATHRBMAPK1 | |
| SCHEMBL18827095 | 0.74 | ALOX15 (0.40) | ALOX15ALDH1A1LMNATHRBMAPK1 | |
| SCHEMBL8739817 | 0.73 | ALOX15 (0.46) | ALOX15ALDH1A1LMNATHRBMAPK1 | |
| SCHEMBL8737958 | 0.68 | ALOX15 (0.64) | ALOX15ALDH1A1LMNATHRBMAPK1 | |
| SCHEMBL3506539 | 0.68 | ALOX15 (0.64) | ALOX15ALDH1A1LMNATHRBMAPK1 | |
| SCHEMBL14252530 | 0.68 | ALOX15 (0.64) | ALOX15ALDH1A1LMNATHRBMAPK1 | |
| SCHEMBL19984303 | 0.66 | ALOX15 (0.31) | ALOX15ALDH1A1LMNATHRBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210369640-A1 | COMPOSITION CONTAINING SESQUITERPENE DERIVATIVE AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF MUSCLE DISEASES | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369640-A1 | COMPOSITION CONTAINING SESQUITERPENE DERIVATIVE AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF MUSCLE DISEASES | TNNC1, TNNI3, PYGM | ALOX15 166/4885ALDH1A1 2633/4885LMNA 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.